



RADIOMOLECULAR PRECISION ONCOLOGY

FOR PATIENTS WORLDWIDE

THE ICPO FOUNDATION.

ICPO THERANOSTICS VIRTUAL SUMMIT

NOV 12 & 13, 2026 - PROGRAM



CHAIRS



Prof. Richard
P. Baum



Prof. Frederik
L. Giesel



Prof. Rudolf
A. Werner



Odile Jaume
CEO



Susanne Simon
Head of Communications

MODERATORS

Interact Live with the Chairs From the ICPO Studio and Grow Your Knowledge Regarding:



Rising Stars in Theranostics



Growing Space of Alphas



Clinical Trials Planning



Leveraging AI in Theranostics Globally



Recommendations to Grow Patient Access Over the Next 5 Years

REGISTER
HERE:



With support from:



WWW.ICPO.FOUNDATION

ICPO THERANOSTICS VIRTUAL SUMMIT

ADOPTING NEW RADIOPHARMACEUTICALS AT YOUR THERANOSTICS CENTER



DAY 1: NOV 12, 2026 – CET TIME ZONE

Welcome by the Chairman and CEO of the ICPO Foundation
followed by the Summit Chairs
2:00 - 2:15 pm



Udo J.
Vetter



Odile
Jaume



Richard
P. Baum



Frederik
L. Giesel



Rudolf
A. Werner

KEYNOTE: From Imaging to Cure:
Theranostics as a Core Pillar in
Today's Oncology, 2:15 - 2:35 pm



Michael Hofman

SESSION I: Outlook into Gen Emitters
2:35 - 3:25 pm



**Reminiscence of Y90 DOTATOC
for NET**

Richard P. Baum



**Selection of optimal Radionuclide:
Efficacy and Safety of Tb161
versus Lu177**

Cristina Mueller



**Clinical Potential of Tb161 for
Radioligand Therapy**

Damian Wild

SESSION II: Clinical Trends in Alpha Corner
3:25 - 4:25 pm



Ac225 Insights in Latest Trials

Mike Sathekge



**Latest Clinical Advances in
Astatine (At211)**

Tadashi Watabe



**Novel Development and Dosing
Strategies for Alpha Therapies,
ADVC001 (Pb212) Experience**

Anna Karmann



Pb212 Beyond Prostate Cancer

Michael Schultz

PANEL 1: Alpha Only Approach: Potential & Effectiveness? Benchmark with Combination Therapies?
4:30 - 4:55 pm

Moderators



Richard
P. Baum



Frederik
L. Giesel

Panelists



Ebrahim
Delpassand



Cristina
Müller



Mike
Sathekge



Tadashi
Watabe

BREAK: 4:55 5:05 pm

ICPO THERANOSTICS VIRTUAL SUMMIT

ADOPTING NEW RADIOPHARMACEUTICALS AT YOUR THERANOSTICS CENTER



DAY 1: NOV 12, 2026 – CET TIME ZONE

SESSION III: Sunrise of FAP & Other Compounds on the Horizon 5:05 - 5:55 pm



FAP-based Radiotheranostics for the Treatment of Diverse Adenocarcinomas and Sarcomas
Elisabetta Perrone



3rd Generation of PSMA
Steven Rowe



Novel Targets incl. CAIX, PL1 and Others
Masato Murakami

SESSION IV: Will “Big” or “Small” Shape The Future? What Space for Pre-Targeting? 5:55 - 6:40 pm



Perspective from Radiopharmaceutical Innovation
Jens Cardinale



Perspective from Clinical Radiochemistry
Jason Lewis



Perspective from Translational Nuclear Medicine
Susanne Lütje

PANEL 2: Is FAP Revolutionary in Terms of Patient Outcomes? Will it Become the New Gold Standard for All Theranostics Centers? 6:45 - 7:10 pm

Moderators



Frederik L. Giesel



Rudolf A. Werner

Panelists



Jason Lewis



Sherly Mosessian



Masato Muakami



Steven Rowe

Wrap Up and Closing of Day 1: Impressions from Richard P. Baum, Frederik L. Giesel, Rudolf A. Werner Closing - Odile Jaume & Susanne Simon 7:10 - 7:15 pm



Richard P. Baum



Frederik L. Giesel



Rudolf A. Werner



Odile Jaume



Susanne Simon

ICPO THERANOSTICS VIRTUAL SUMMIT

PLANNING AND NAVIGATING CLINICAL TRIALS AT YOUR THERANOSTICS CENTER

DAY 2: NOV 13, 2026 – CET TIME ZONE



WELCOME By the CEO
of the ICPO FOUNDATION
10:00 - 10:05 am



Odile Jaume

KEYNOTE: Future Outlook Into
Radiotheranostics
10:05 - 10:25 am



Ken Herrmann

SESSION V: Planning Your Clinical Trial
10:25 - 11:15 am



**Current and Future Design of
Theranostics Clinical Trials**
Igor Rakovic



Structuring & Managing Trial Data
Sam Vohra



**Listening to Patients Advocates on
Clinical Trials**
Erik Briers

**SESSION VI: Navigating Trial Design
Involving Novel Approaches:** 11:15 - 12:00 am



**First Use of Re188-PSMA, as Tc99m-
PSMA Companion:**
Mike Sathekge



**uPAR-targeted PET Imaging Tracers
in Oncology Research –** Andreas
Kjaer



**Role of Genomics & Transcriptomics
or when in Vitro Meets in Vivo**
Ralph Wirtz

PANEL 3: Highlights of a PRRT Patient Journey and Lessons Learned
12:00 - 12:25 am

Moderator

Panelists



Rudolf A.
Werner



Tiphaine
Locqueneux



Meredith
Cummins



Ken
Herrmann

BREAK: 12:25 - 12:35 am

ICPO THERANOSTICS VIRTUAL SUMMIT

PLANNING AND NAVIGATING CLINICAL TRIALS AT YOUR THERANOSTICS CENTER



DAY 2: NOV 13, 2026 – CET TIME ZONE

SESSION VII: How To Reach And Select Patients For Your Trials?

12:35 - 1:25 pm



Theranostics Patient Selection at Large Volume Cancer Center

Désirée Deandreis



Challenges and Opportunities in Patient Recruitment for Theranostics in Emerging Research Centers

Cecilia Carreras



Leveraging Ancora.ai Radiopharmaceuticals Trial Finder

Danielle Ralic

SESSION VIII: Leveraging AI In Theranostics At Your Center

1:25-2:15 pm



Leveraging AI to Advance Clinical Theranostics Globally

Johannes Tran-Gia



Empowering AI in Clinical Trials

Vikas Prasad



ARCHE: An AI-driven Curation and Harmonization Engine for Structuring Multimodal Theranostics Data

Lalith Sundar

PANEL 4 / FINAL ROUND TABLE: Essential Recommendations to Grow Patient Access to Radiotheranostics Innovation Over the Next 5 Years?

2:15 - 2:40 pm

Moderators



Richard P. Baum



Frederik L. Giesel



Rudolf A. Werner

Panelists



Akram Al-Ibraheem



Désirée Deandreis



Vikas Prasad

Wrap up of ICPO Summit 2026 by the Chairs Richard P. Baum, Frederik L. Giesel and Rudolf A. Werner. Closing by Odile Jaume and Susanne Simon

2:40 - 3:00 pm



Richard P. Baum



Frederik L. Giesel



Rudolf A. Werner



Odile Jaume



Susanne Simon

THANK YOU FOR YOUR ATTENTION
CONTACT ICPO FOUNDATION: INFO@ICPO.FOUNDATION